The Claim
The combination of rosuvastatin and ezetimibe is associated with a higher incidence of statin-associated muscle symptoms and liver enzyme elevation compared to rosuvastatin monotherapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People taking both rosuvastatin and ezetimibe together experience more muscle symptoms and higher liver enzyme levels than those taking rosuvastatin alone.
See the scientific wording
The combination of rosuvastatin and ezetimibe is associated with a higher risk of both statin-associated muscle symptoms and liver enzyme elevation compared to rosuvastatin monotherapy, suggesting that drug interactions may amplify adverse effects in genetically susceptible individuals.
When two drugs block the same liver transporters, more statin stays in the blood and enters the liver and muscles. In the liver, too much statin damages cells and causes enzymes to leak into the blood. In the muscles, too much statin breaks down energy production in mitochondria, leading to muscle pain and weakness.
What the research says
1 studyTaking rosuvastatin with ezetimibe made muscle pain and liver problems worse than taking rosuvastatin alone, especially in people with certain genes, according to this study.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.